As many veteran investors can attest, biotech stocks are tricky to trade. Their potential upside is enormous, but so is their risk. Too many of these names end up being complete busts. If you pick the ...

Two of the leading companies in the AI drug development field, Recursion Pharmaceuticals and Exscientia, said Thursday that they will merge into one company. The new company will continue using the ...

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...

High-rolling investors have positioned themselves bullish on Recursion Pharmaceuticals (NASDAQ:RXRX), and it's important for retail traders to take note. \This activity came to our attention today ...

Recursion Pharmaceuticals wants to disrupt drug development. It's leaning on new information technology and automation methods. For the moment, it lacks any big wins to point to. The company is ...

Recursion Pharmaceuticals lacks any of the long history of consistent performance that Buffett favors. Nonetheless, it aspires to become a business with characteristics he might like. It'll take a few ...

Biotech Recursion announced a definitive merger agreement with drug design and development company Exscientia on Thursday morning. The combined company, which is expected to yield annual synergies of ...

The market is viewing NVIDIA's decision to keep its 7.7 million share stake in Recursion while divesting from other AI holdings as a significant strategic move. This decision indicates NVIDIA's ...

Companies whose breakthroughs revolutionize industries often end up being massively successful. Think Netflix's move from DVDs to streaming, or Apple's innovative smartphone that killed BlackBerry's ...

Recursion Pharmaceuticals (RXRX) closed at $4.77 in the latest trading session, marking a -1.24% move from the prior day.